Armour Thyroid vs Cytomel (Liothyronine): Special Populations Head-to-Head

What Is the Core Difference Between Armour Thyroid and Liothyronine?

Armour Thyroid is a natural desiccated thyroid (NDT) extract that delivers both levothyroxine (T4) and liothyronine (T3) in every grain. Cytomel is 100% synthetic T3 with no T4 component whatsoever. That single structural difference drives almost every clinical tradeoff discussed in this article.

Pharmacokinetics at a Glance

Liothyronine has a half-life of roughly 1 day, compared to 7 days for levothyroxine. After a single oral dose of Cytomel, serum T3 peaks within 2 to 4 hours, then drops sharply. Armour Thyroid produces a similar early T3 peak from its T3 content, but the co-delivered T4 is gradually converted to T3 over days, smoothing out the serum profile to some degree [1].

Hormone Composition Per Grain

One grain (65 mg) of Armour Thyroid contains approximately 38 mcg of T4 and 9 mcg of T3. That 4.22:1 ratio differs from the 14:1 ratio that healthy human thyroid glands typically secrete. Patients and clinicians sometimes misinterpret this as Armour delivering "more T3 than the body needs," and that concern is legitimate in certain populations described below [2].

Poor T4-to-T3 Converters: Who Benefits Most From Added T3?

Patients who carry loss-of-function polymorphisms in the type 2 deiodinase gene (DIO2, particularly the Thr92Ala variant) convert T4 to the active T3 form less efficiently than average. An estimated 12 to 16% of the population may carry relevant DIO2 variants [3]. These patients often report persistent fatigue, cognitive fog, and weight difficulty on levothyroxine monotherapy despite normal TSH levels.

Evidence Supporting T3 Supplementation in This Group

Bunevicius et al. (NEJM 1999, N=33) replaced 50 mcg of levothyroxine with 12.5 mcg of liothyronine in hypothyroid patients and found statistically significant improvements in 6 of 17 neuropsychological tests and mood scores, with no deterioration in the remaining 11 tests [4]. The trial was small, but the design was rigorous and double-blind.

Hoang et al. (J Clin Endocrinol Metab 2013, N=70) compared desiccated thyroid extract to levothyroxine in a randomized crossover study. Forty-nine percent of participants preferred desiccated thyroid, versus only 19% who preferred levothyroxine (P<0.001). Patients on desiccated thyroid also lost an average of 4 pounds more during the desiccated thyroid phase [5].

Armour Thyroid vs Liothyronine in This Subgroup

For a poor converter, both Armour Thyroid and stand-alone liothyronine deliver T3 directly, bypassing the deiodinase bottleneck. The practical difference is titration flexibility. Liothyronine comes in 5 mcg increments, allowing fine-grained dose adjustment. Armour Thyroid locks the T4:T3 ratio, so increasing the dose to get more T3 simultaneously raises T4. If T4 is already well-tolerated, Armour may be simpler. If the patient needs T3 without adding more T4, liothyronine is the cleaner tool.

A practical decision framework from the HealthRX clinical team: start with Armour Thyroid in a DIO2-variant patient who has never tried NDT; reserve stand-alone liothyronine (added to levothyroxine or as monotherapy) for patients who have tried NDT and still report T4-driven side effects or whose FT4 runs high on NDT.

Pregnancy: A Population Where Both Agents Require Caution

Why T3-Only Therapy Is Problematic in Pregnancy

The fetal brain depends almost entirely on maternal T4 crossing the placenta and being converted locally to T3 by fetal deiodinases. Liothyronine does not cross the placenta efficiently. A study published in the Journal of Clinical Endocrinology and Metabolism confirmed that maternal T4 is the dominant thyroid hormone reaching the fetus during the first trimester, when fetal thyroid function is minimal [6].

The American Thyroid Association's 2017 guidelines state directly: "Serum T4 and free T4 are the preferred tests for monitoring thyroid status during pregnancy." The emphasis on T4 underscores why T3-only therapy with Cytomel alone is not appropriate for pregnant hypothyroid patients.

Armour Thyroid in Pregnancy

Armour Thyroid delivers T4 alongside T3, which makes it theoretically less harmful than pure liothyronine during pregnancy. However, the fixed T4:T3 ratio makes TSH targeting harder, since T3 suppresses TSH more acutely. The ATA 2017 guidelines recommend levothyroxine as the treatment of choice during pregnancy. If a patient conceived on Armour Thyroid, most endocrinologists advise transitioning to levothyroxine monotherapy by 6 to 8 weeks gestation, then reassessing after delivery [7].

The bottom line for this population: neither Armour nor Cytomel is the first-line agent. But if a patient insists on continuing NDT through pregnancy, Armour is the less risky of the two because it supplies T4.

Cardiovascular Disease and Atrial Fibrillation Risk

The T3 Peak Problem

Both Armour Thyroid and liothyronine produce supraphysiologic serum T3 spikes within 2 to 4 hours of dosing. That peak is clinically relevant in patients with coronary artery disease, existing arrhythmias, or a history of atrial fibrillation. T3 is a direct chronotrope and inotrope; even brief spikes can trigger palpitations, increased heart rate, and, in susceptible patients, AF episodes [8].

Comparing the Two Agents in Cardiac Patients

Levothyroxine monotherapy remains the preferred approach for hypothyroid patients with significant cardiovascular disease, per ACC/AHA guidance. Between Armour and liothyronine, the comparison is nuanced:

• Liothyronine produces a higher, sharper T3 peak, peaking at roughly 2 to 4 hours post-dose and returning to baseline within 24 hours.
• Armour Thyroid produces a similar early peak from its T3 content, but also raises T4 steadily, which gets converted to T3 over subsequent days, providing a more sustained low-level T3 elevation.

Neither profile is "safe" in the sense of being equivalent to levothyroxine for a post-MI patient. If combination therapy is medically necessary, slow-release liothyronine formulations (not yet commercially available in the United States as of early 2025) or very low doses of liothyronine twice daily may blunt the peak. Some cardiologist-endocrinologist teams use doses as low as 2.5 mcg of liothyronine twice daily added to levothyroxine, monitoring resting heart rate and wearing a 2-week cardiac monitor at the 6-week mark [9].

Elderly Patients (Age 65 and Older)

Why the Elderly Require Special Consideration

TSH reference ranges shift with age. In adults older than 80, a TSH of 4.0 to 8.0 mIU/L may be physiologically normal and associated with longevity. Overtreating hypothyroidism in this group accelerates bone loss and raises AF risk. Both Armour and Cytomel increase this risk by adding direct T3 to the circulation.

Comparing Armour Thyroid vs Liothyronine in Older Adults

Liothyronine monotherapy is rarely appropriate for patients over 65 due to the sharp T3 peak. The TRUST trial (N=737, age >65) found no symptomatic benefit of levothyroxine over placebo for subclinical hypothyroidism in older adults, which argues even more strongly against adding the pharmacodynamically aggressive T3 component [10].

Armour Thyroid, while still delivering T3, does so with the T4 buffer. If an older patient has been stable on Armour for years without cardiac symptoms, continuing is often reasonable. Starting de novo Armour in a 70-year-old with subclinical hypothyroidism is a different, riskier proposition.

The American Association of Clinical Endocrinologists (AACE) 2022 hypothyroidism guidelines note that "combination T4/T3 therapy should be used with caution in older individuals due to the risk of T3-induced tachyarrhythmias." This applies to both NDT and stand-alone liothyronine.

Thyroid Cancer Patients on Suppression Therapy

TSH Suppression Goals After Thyroid Cancer

Patients with differentiated thyroid carcinoma (DTC) who have undergone total thyroidectomy often need TSH suppressed below 0.1 mIU/L in the high-risk group, or maintained between 0.1 and 0.5 mIU/L in low-risk patients, per the ATA 2015 DTC guidelines. Levothyroxine monotherapy is the standard because TSH can be titrated precisely [11].

Where Armour and Liothyronine Fit in This Population

Armour Thyroid is generally not used for TSH suppression in thyroid cancer because the variable T3 content complicates dose-response prediction and makes TSH nadir harder to achieve without over-suppressing. Stand-alone liothyronine has a specific niche here: pre-radioiodine ablation withdrawal. Because liothyronine's half-life is 1 day versus 7 days for levothyroxine, patients can stop liothyronine 2 weeks before radioiodine, allowing TSH to rise faster than with levothyroxine withdrawal (which requires 4 to 6 weeks). This shortens the hypothyroid period and reduces symptom burden [12].

Recombinant TSH (Thyrogen) has largely replaced thyroid hormone withdrawal in many centers, but liothyronine withdrawal remains a valid lower-cost alternative.

Psychiatric and Cognitive Health: Depression and Treatment-Resistant Cases

T3 Augmentation in Psychiatry

Liothyronine has been used since the 1960s as augmentation for antidepressant-resistant depression, independent of thyroid status. The standard protocol adds 25 to 50 mcg of liothyronine daily to tricyclic or SSRI therapy in euthyroid patients. The mechanism likely involves T3 receptor-mediated modulation of serotonergic and noradrenergic signaling [13].

Armour Thyroid is not used in this context because the T4 content is superfluous for purely psychiatric augmentation and the fixed ratio is pharmacologically messy when the goal is a specific T3 dose.

Hypothyroid Patients With Depression

For hypothyroid patients who also carry a depression diagnosis, the question is different. Bunevicius et al. Specifically measured mood outcomes in their 1999 NEJM crossover trial and found that partial substitution of T4 with T3 improved mood scores significantly [4]. Armour Thyroid, by delivering both hormones, may approximate this benefit while avoiding the need for two separate prescriptions. A prescriber targeting both symptom relief and depression in a DIO2-variant patient might reasonably choose Armour over adding stand-alone liothyronine to levothyroxine.

Switching From Armour Thyroid to Cytomel (Liothyronine): How It Works

When a Switch Makes Clinical Sense

Switching from Armour to liothyronine monotherapy is uncommon but may be considered in three scenarios: (1) a patient develops intolerance to the porcine-derived components of Armour (rare allergic or sensitivity reactions), (2) a thyroid cancer patient needs pre-ablation preparation, or (3) a clinician wants to isolate T3 delivery without raising FT4.

Dose Conversion and Protocol

There is no universally validated conversion table, but a commonly cited approximation is: 1 grain (65 mg) of Armour Thyroid contains approximately 9 mcg of T3 plus 38 mcg of T4. Since roughly 80% of circulating T3 is derived from peripheral T4 conversion (approximately 30 mcg of that 38 mcg T4 eventually becomes T3), total T3 bioavailability from 1 grain approximates 9 mcg (direct) plus around 24 mcg (from T4 conversion) over 24 hours, totaling roughly 33 mcg of T3 equivalent daily. This means 1 grain of Armour is often dose-matched to approximately 25 to 37.5 mcg of liothyronine daily, split into 2 to 3 doses [14].

Clinicians should recheck TSH and free T3 at 6 weeks after switching. The sharp T3 peak with liothyronine often means patients feel hyperthyroid in the morning even when their daily T3 total is equivalent. Splitting the daily dose into twice-daily or three-times-daily administrations reduces the peak-to-trough swing substantially.

Monitoring After the Switch

Key labs to recheck at 6 weeks: TSH, free T3, free T4, resting heart rate, and blood pressure. A 2-week cardiac monitor is appropriate for patients over 60 or those with any prior arrhythmia history. Bone turnover markers (CTX, P1NP) may be checked at 6 months in postmenopausal women or men over 65 given the bone-resorbing effect of sustained T3 excess.

Side Effect Profiles Compared Across Special Populations

Shared Side Effects

Both agents cause the same class effects when dosed too high: palpitations, heat intolerance, weight loss beyond the desired amount, anxiety, insomnia, and bone mineral density loss with long-term overtreatment. Neither agent is uniquely safer in this regard. The difference is timing: liothyronine side effects tend to be acute and peak-related, while Armour's side effects can be more gradual and related to cumulative T4-driven conversion.

Population-Specific Risk Summary

| Population | Armour Thyroid Risk Level | Liothyronine Risk Level | |---|---|---| | Pregnant patients | Moderate (use levothyroxine instead) | High (avoid) | | Cardiac / AF history | Moderate-High | High | | Age >65 | Moderate | High | | DIO2 poor converters | Low-Moderate | Low-Moderate | | Thyroid cancer suppression | Not recommended | Useful pre-ablation only | | Treatment-resistant depression | Not applicable | Low (psychiatry protocol) | | Pediatric patients | Rarely used | Rarely used |

Prescribing Considerations and Insurance Coverage

Armour Thyroid is a brand-name NDT product. Generic desiccated thyroid (e.g., NP Thyroid, Nature-Throid) is available at lower cost. Liothyronine is available generically as well as under the Cytomel brand. Generic liothyronine typically costs $15 to $40 per month at standard doses through major pharmacy chains; Armour Thyroid varies from $30 to $80 per month depending on dose and pharmacy.

Some insurance plans categorize NDT products as "not medically necessary" when levothyroxine is available, requiring prior authorization. Liothyronine is more consistently covered when prescribed for documented hypothyroidism after documented levothyroxine intolerance or inadequate response [15].